CN102727531A - Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis - Google Patents
Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis Download PDFInfo
- Publication number
- CN102727531A CN102727531A CN2012102539440A CN201210253944A CN102727531A CN 102727531 A CN102727531 A CN 102727531A CN 2012102539440 A CN2012102539440 A CN 2012102539440A CN 201210253944 A CN201210253944 A CN 201210253944A CN 102727531 A CN102727531 A CN 102727531A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- mycopowder
- vaginitis
- treatment
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to active lactic acid bacteria capsules with a treatment and prevention effect on vaginitis. The lactic acid bacteria capsules capable of simultaneously adjusting dysbacteriosis of intestinal tracts and vagina and emphasizing treatment and prevention of the vaginitis are developed for achieving comprehensive effects. According to the technical scheme, excipient and lactic acid bacteria mixed bacteria powder are wrapped in the active lactic acid bacteria capsules with the treatment and prevention effect on vaginitis, and the lactic acid bacteria mixed bacteria powder comprises lactobacillus crispatus powder and other lactic acid bacteria subspecies powder with an effect of adjusting the intestinal flora. The active lactic acid bacteria capsules can be used for treating the vaginitis by adopting oral administration and intra-vaginal use; the oral lactobacillus can effectively improve the immunity of mucosa by stimulating the immune response of the intestinal mucosa, adjust the overall function state of a human body and well treat the vaginitis; and a large quantity of lactobacillus proliferated in the intestinal tract can inhibit growth of intestinal bacteria and reduce the risk of intestinal bacteria infection in vagina.
Description
Technical field
The invention belongs to and a kind of vaginitis is had the treatment and the medicine of preventive effect, relate in particular to a kind of vaginitis is had treat and the Lactobacillus capsule of preventive effect.
Background technology
Vaginitis is a kind of very common vaginal infection property disease; In recent years, along with the development of microecology, medical circle has been recognized gradually that microecology in vaginas is equilibrated in the morbidity of women vaginitis and has been occupied very consequence; Microecology in vaginas is learned viewpoint and is thought; There is one in the healthy women intravaginal, and wherein the antibacterial more than 90% is the vagina lactobacillus by hundreds of millions of microecosystems that antibacterial constituted, and they are main executives of vagina defense function; The vagina lactobacillus can be through producing lactic acid; Keep sour environment, mechanism such as competition adheres to, enhancing vaginal mucosa immunity are resisted the invasion of pathogenic bacterium such as mycete, escherichia coli and staphylococcus aureus, and the women's that ability of Lactobacillus in human vagina content is many vaginitis incidence probability all contains the women of a large amount of lactobacilluss much smaller than intravaginal.
Based on this point, all developed many vaginas both at home and abroad thereupon and treated vaginitis with microbial ecological agent.But the used strain of microecology in vaginas preparation is not the intravaginal dominant bacteria; Because great majority research both at home and abroad all proves; Modal lactobacillus lactis subsp is Lactobacillus crispatus (L.crispatus) in the healthy women vagina, this field planting in vagina the most easily.What Verhelst etc. carried out discovers; Vagina cleanness degree is in the vaginal secretions sample of I degree; The separation rate of Lactobacillus crispatus (L.crispatus) is the highest; Can reach 52.1%, this shows related the most closely (Rita Verhelst, 2005) of vagina cleanness degree I degree and Lactobacillus crispatus.Kwok etc. discover that to the 101 routine women of child-bearing age's Lactobacillus crispatus (L.crispatus) is stronger to the adhesiveness of vaginal epithelial cell, and with recent sexual intercourse number of times, whether use no obvious dependencys such as spermicide.These explain that all Lactobacillus crispatus is stronger in intravaginal field planting ability, is best suited for the strain as the microecology in vaginas preparation.
Yet; The strain factor is the factor of lactobacillus in intravaginal field planting; Good strain is merely able to explain that its probability of field planting in vagina is bigger, and lactobacillus is a very complicated process in intravaginal field planting, is a human long-term result who evolves naturally; Be the result of the mutual selection of host and antibacterial; Up to now, the lactobacillus of separating from intravaginal in the women reaches 16 kinds, and host's vagina microenvironment itself and body's immunological function state have all determined whether to be fit to the field planting of certain lactobacillus.So; Lactobacillus in the microbial ecological agent that single culture is processed can not all be adapted at field planting in all host's vaginas; Different this facts that just proved to a certain extent of mother and daughter's ability of Lactobacillus in human vagina strain; In addition; A kind of all pathogenic bacterium are all had the strain that suppresses ability very by force also very difficult the finding of nature, require a great deal of time and fund, but of addressing these problems is effective and simple measure is exactly to select for use more than one lactobacillus lactis subsp to prepare the microecology in vaginas preparation.
In addition, vagina is an ingredient of human body, and the immunologic function of colpitic generation and animal economy and metabolism state especially exist contact very closely between the intestinal.Mainly show as 4 points: though 1, intestinal and vagina separate on dissecting; But distance is approaching by very; Many antibacterials such as lactobacillus, bacillus bifidus, enterococcus and escherichia coli etc. in the intestinal can be colonizated in intravaginal; Become the probiotics or the pathogenic bacterium of vagina, suppress the interior pathogenic bacterium quantity of intestinal and then can reduce the vaginitis incidence rate; 2, the two belongs to the mucosal barrier system; Can induce the mucosal immunoreaction of the whole body that comprises vaginal mucosa through intestinal mucosa, vice versa, but because the intestinal endolymphatic system is than abundant many of intravaginal; Induce the mucosa reaction of whole body more easily through intestinal; Some secretory IgA, sIgAs whole body that can circulate, and can secreting to intravaginal by the transvaginal mucosa, thus the anti-infection ability of vaginal mucosa can be strengthened; 3, after female patient had used heavy dose of antibiotic therapy, dysbacteriosis all can take place in intestinal and vagina, can cause enteritis and vaginitis simultaneously, and just the vaginitis performance is relatively more obvious; 4, whether function of intestinal canal normally directly influences the digestive and absorptive functions of this human body and influences the animal economy functional status, thereby influences other various diseases ability that the body antagonism comprises vaginitis.
In sum, the exploitation vaginitis is especially for due to the broad ectrum antibiotic during colpitic medicine; Can not only be confined to rebuild this local ecosystem's system of vaginal microbial flora balance; Should regard human body as an integral body, in adjustment vaginal microbial flora, also will note adjusting intestinal microbial population, improve the mucosal immunity power of body simultaneously; The integrality of adjustment body; The present invention starts with from integral body, develops and can adjust intestinal and vaginal dysbacteriosis simultaneously, prevents and treat colpitic lactobacillus capsule emphatically.
Application number is that 200710193035.1 invention has related to a kind of Deshi Lactobacillus capsule; Lactobacillus wherein is a Deshi Lactobacillus; According to bibliographical information, Deshi Lactobacillus separation rate in the healthy women vagina is lower, less than 1%; This lactobacillus more is common in the intestinal, will not be highly suitable for field planting in most of people's the vagina on the acting in accordance with YIN YANG changes in four seasons source.Application number is that 200910024226.4 invention has related to a kind of intestinal streptococcus capsule alive; The intestinal streptococcus is enterococcal a kind of, though also be lactobacillus, its separation rate in the healthy women vagina is low; Also be more to be common in the intestinal; And according to bibliographical information, the intestinal streptococcus is a conditioned pathogen, though do not cure the disease under normal operation; But might cause urinary tract infection, suppurative abdominal infection, septicemia, endocarditis and diarrhoea fever etc.; Have potential danger, its safety is not as lactobacillus, and international probiotic bacteria association (International Probiotics Association) and The World Health Organization (WHO) all advise: should not use enterococcus in the probiotic bacteria.In addition,, only be confined on the adjustment vaginal microbial flora, human body do not considered as a whole removing because the thinking of these two inventions is also too narrow.
Summary of the invention
The purpose of this invention is to provide a kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect.
For solving the problems of the technologies described above, the technical scheme that the present invention adopts is:
A kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect; Be enclosed with excipient and lactobacillus mixing mycopowder in the described capsule, described lactobacillus mixing mycopowder comprises Lactobacillus crispatus mycopowder and other lactobacillus subspecies mycopowder with the effect of adjustment intestinal microbial population.
Further, described Lactobacillus crispatus mycopowder is 1 with the weight ratio of other lactobacillus subspecies mycopowder with the effect of adjustment intestinal microbial population: (1 ~ 100), the weight ratio of described excipient and lactobacillus mixing mycopowder is (1 ~ 10): 1.
Further, described Lactobacillus crispatus is the bacterial strain of separating in the healthy women vagina.
Further, described other lactobacillus subspecies mycopowder with adjustment intestinal microbial population effect refers to one or more the mixture in bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder, lactobacillus rhamnosus mycopowder and the bacillus bifidus mycopowder.
Further, described lactobacillus subspecies mycopowder with the effect of adjustment intestinal microbial population is the lactobacillus rhamnosus mycopowder.
Further, described excipient is a microcrystalline Cellulose.
Further, the total viable count of described Lactobacillus crispatus mycopowder is 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of described bacillus acidophilus's mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of Lactobacillus fermenti mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of lactobacillus rhamnosus mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of bacillus bifidus mycopowder be 1 * 10
6To 1 * 10
12Between individual/g.
Further, described a kind of total viable count that vaginitis is had a lactobacillus mixing mycopowder in the treatment and the Lactobacillus capsule of preventive effect is 1 * 10
6To 1 * 10
12Between individual/capsules.
Preferred version of the present invention is a kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect; Be enclosed with excipient and lactobacillus mixing mycopowder in the described capsule; Described lactobacillus mixing mycopowder comprises Lactobacillus crispatus mycopowder and lactobacillus rhamnosus mycopowder; Said excipient is a microcrystalline Cellulose, wherein the Lactobacillus crispatus mycopowder: the lactobacillus rhamnosus mycopowder: the weight ratio of excipient is 1:1:1.
Further, described have treatment and the capsular route of administration of Lactobacillus of preventive effect is oral and/or vaginal approach to vaginitis.
Beneficial effect of the present invention:
With the comparison of existing invention, advantage of the present invention is:
1, first-selection has been selected a kind of lactobacillus lactis subsp more common in the healthy women vagina---Lactobacillus crispatus; There are a large amount of documents and test to think that Lactobacillus crispatus is more suitable in the intravaginal field planting; This is human vagina and the long-term result who selects each other of lactobacillus, uses this lactobacillus also just to rebuild the colony balance of vagina more easily; The present invention simultaneously is made up of two kinds of lactobacillus lactis subsps, has increased the range of choice of vagina, and the host range that accommodates field planting will further enlarge.A strain wants long-term role, must be in the medium-term and long-term definite value of vagina, otherwise how preferred strain to the bacterium that also just passes by on one's way, can not be brought into play prevention and therapeutical effect for a long time again.
2, the strain in above-mentioned two kinds of inventions wants to obtain said strain in above-mentioned two inventions because in the crowd, exist ratio lower, just as looking for a needle in a haystack, needs to drop into a large amount of energy and times, is very difficult to obtain.And used lactobacillus strain is all more common among the present invention, is very easy to obtain.
3, the thinking of original invention is also too narrow, only has been confined on the adjustment vaginal microbial flora, human body is not considered as a whole removing; A kind of strain of the present invention is strong in vagina field planting power; A little less than the field planting ability of intestinal, a kind of strain field planting ability in intestinal is strong, a little less than the field planting ability of vagina (strong and weak is comparatively speaking); On the basis of stressing reconstruction vaginal microbial flora, also pay attention to the adjustment intestinal microbial population, improve the whole mucosal immunity power of body.Lactobacillus capsule among the present invention can be taked oral simultaneously and intravaginal uses two kinds of approach to remove to treat vaginitis; Orally administering lactobacillus can improve mucosal immunity power effectively through exciting the intestinal mucosa immunoreation; The allomeric function state of adjustment human body could be treated vaginitis so better.In addition, lactobacillus a large amount of propagation in intestinal can suppress the growth of intestinal bacteria, also can reduce the risk of vaginal infection intestinal bacteria.
4, in recent years, begin to use in a large number broad ectrum antibiotic treatment infectious disease clinically, this Therapeutic Method is when removing infectious bacteria; Also having killed intestinal and intravaginal probiotics, mainly is exactly lactobacillus, can cause intestinal and vaginal dysbacteriosis; Thereby cause a series of diseases such as vaginitis, enteritis, for the women, colpitic performance is more obvious; Because for intestinal microbial population, intravaginal flora structure is single relatively, and is fragile more; Take after a large amount of antibiotic, female patient mainly shows as vaginitis, but the general also alteration of intestinal flora of various degrees simultaneously.The present invention can solve two kinds performance is different with a kind of capsule but vaginitis and enteritis due to the dysbacteriosis that essence is identical, and this is preceding the not creation of usefulness.
5, adopt vaginal approach cumbersome during common vaginal capsule long-term prescription; The present invention then can the oral administration administration, also can the transvaginal administration, and can take two kinds of approach to treat simultaneously; The patient can freely select route of administration; Select oral administration can improve compliance, for a long time oral have the health-care effect that is similar to yoghourt but is superior to, and can prevent colpitic recurrence; In addition, the present invention can select for use microcrystalline Cellulose as excipient, can absorb water fast during vagina medicinal, accelerates the capsule disintegrate, promotes active lactobacillus to discharge, and itself is exactly a kind of dietary fiber, can also play the effect of adjustment intestinal after oral.
6, the selected strain of the present invention all requires to come among healthy human body vagina, intestinal or the yoghourt, does not have any potential pathogenic risk, and safety is good.
The specific embodiment
Below in conjunction with concrete embodiment the present invention is done further explanation.
Embodiment 1 ~ 6
The first step of the present invention is set up corresponding lactobacillus inoculation word bank exactly.
The foundation of Lactobacillus crispatus seed bank
1, collect the vagina secretions of the scorching medical history of absence of vagina, it is subsequent use to use normal saline that secretions is carried out putting into 4 ℃ of refrigerators behind the serial dilution, and the holding time is no more than 3 days.
2, configuration standard MRS solid medium is poured into behind 121 ℃ of autoclavings in the 10 cm plates, and it is subsequent use to put into 4 ℃ of refrigerators after to be cooled the solidifying.
3, draw 200 microlitre vaginal secretions diluents in the MRS flat board, insert in the anaerobic jar after the coating evenly of use spreading rod, under 37 ℃ of conditions, cultivated 48 hours.
4, the single bacterial clone of picking; Carry out Gram's staining; With Grain-positive bacillus clone amplification culture; Use conventional bacteria culture to identify that required biochemistry and Protocols in Molecular Biology identify, put into-80 ℃ of refrigerators after the mixed of glycerol with the strain that is accredited as Lactobacillus crispatus and 40% and preserve, as Lactobacillus crispatus original species word bank by 1:1.
5, use the Lactobacillus crispatus primordial seed to carry out amplification culture, set up Lactobacillus crispatus work seed bank.
Foundation with lactobacillus subspecies seed bank of adjustment intestinal microbial population effect is
1, collect to gather healthy human body feces, healthy babies feces or commercially available yoghourt BIAO and BEN, it is subsequent use to use normal saline that the BIAO and BEN of collecting is carried out putting into 4 ℃ of refrigerators behind the serial dilution, and the holding time is no more than 3 days.
2, configuration standard MRS solid medium is poured into behind 121 ℃ of autoclavings in the 10 cm plates, and it is subsequent use to put into 4 ℃ of refrigerators after to be cooled the solidifying.
3, draw 200 microlitre sample diluents in the MRS flat board, insert in the anaerobic jar after the coating evenly of use spreading rod, under 37 ℃ of conditions, cultivated 48 hours.
4, the single bacterial clone of picking; Carry out Gram's staining; With Grain-positive bacillus clone amplification culture; Use conventional bacteria culture to identify that required biochemistry and Protocols in Molecular Biology identify; To be accredited as bacillus acidophilus (L. acidophilus), Lactobacillus fermenti (L.fermentum), lactobacillus rhamnosus (L. rhamnosus), bacillus bifidus (Bifidobacterium) and put into-80 ℃ of refrigerators and preserve respectively with after 40% the mixed of glycerol, as bacillus acidophilus (L. acidophilus) original species word bank, Lactobacillus fermenti (L.fermentum) original species word bank, lactobacillus rhamnosus (L. rhamnosus) original species word bank and bacillus bifidus (Bifidobacterium) original species word bank by 1:1.
5, use bacillus acidophilus (L. acidophilus) primordial seed, Lactobacillus fermenti (L.fermentum) primordial seed, lactobacillus rhamnosus (L. rhamnosus) primordial seed and bacillus bifidus (Bifidobacterium) primordial seed to carry out amplification culture respectively, set up bacillus acidophilus (L. acidophilus) work seed bank, Lactobacillus fermenti (L.fermentum) work seed bank, lactobacillus rhamnosus (L. rhamnosus) work seed bank and bacillus bifidus (Bifidobacterium) work seed bank.
Embodiment 1
A kind of capsular preparation of Lactobacillus that vaginitis is had treatment and preventive effect
One, from vaginal secretions, separates Lactobacillus crispatus and set up the Lactobacillus crispatus seed bank
1, collect the vagina secretions of the scorching medical history of absence of vagina, it is subsequent use to use normal saline that secretions is carried out putting into 4 ℃ of refrigerators behind the serial dilution, and the holding time is no more than 3 days.
2, configuration standard MRS solid medium is poured into behind 121 ℃ of autoclavings in the 10 cm plates, and it is subsequent use to put into 4 ℃ of refrigerators after to be cooled the solidifying.
3, draw 200 microlitre vaginal secretions diluents in the MRS flat board, insert in the anaerobic jar after the coating evenly of use spreading rod, under 37 ℃ of conditions, cultivated 48 hours.
4, the single bacterial clone of picking; Carry out Gram's staining; With Grain-positive bacillus clone amplification culture; Use conventional bacteria culture to identify that required biochemistry and Protocols in Molecular Biology identify, put into-80 ℃ of refrigerators after the mixed of glycerol with the strain that is accredited as Lactobacillus crispatus and 40% and preserve, as Lactobacillus crispatus original species word bank by 1:1.
5, use the Lactobacillus crispatus primordial seed to carry out amplification culture, set up Lactobacillus crispatus work seed bank.
Two,The preparation of Lactobacillus crispatus mycopowder
1, gets 1 milliliter of strain from Lactobacillus crispatus work seed bank; Carry out the amplification culture step by step of 20ml, 400 ml, 8000ml and 160L, condition of culture is 37 ℃, the discontinuous stir culture of low speed; Cultivated 22 hours, during sampling Detection pH value and thalline OD value estimate its growing state.
2, use change for 4 ℃, 4500, centrifugal 15 minutes conditional capture thalline, use the resuspended thalline of liquid freeze drying protectant behind the autoclaving, left standstill 1 hour.
3, bacterium liquid is poured in the freezer dryer loading tray; Liquid level is no more than 12 mm, and pre-freeze 6 hours under the condition of-80 degree was carried out drying 36 hours afterwards under vacuum condition then; Promptly obtain the Lactobacillus crispatus mycopowder behind dry the end, put into after the sealing in the aluminium plastic bag of packing into-20 ℃ subsequent use.The total viable count of the Lactobacillus crispatus mycopowder of preparation is 1 * 10
6To 1 * 10
12Between individual/g.
Three, the preparation of lactobacillus rhamnosus (L. rhamnosus) seed bank and mycopowder
1, collect to gather healthy human body feces, healthy babies feces or commercially available yoghourt BIAO and BEN, it is subsequent use to use normal saline that the BIAO and BEN of collecting is carried out putting into 4 ℃ of refrigerators behind the serial dilution, and the holding time is no more than 3 days.
2, configuration standard MRS solid medium is poured into behind 121 ℃ of autoclavings in the 10 cm plates, and it is subsequent use to put into 4 ℃ of refrigerators after to be cooled the solidifying.
3, draw 200 microlitre sample diluents in the MRS flat board, insert in the anaerobic jar after the coating evenly of use spreading rod, under 37 ℃ of conditions, cultivated 48 hours.
4, the single bacterial clone of picking; Carry out Gram's staining; With Grain-positive bacillus clone amplification culture; Use conventional bacteria culture to identify that required biochemistry and Protocols in Molecular Biology identify, will be accredited as lactobacillus rhamnosus (L. rhamnosus) and put into-80 ℃ of refrigerators and preserve respectively with after 40% the mixed of glycerol, as lactobacillus rhamnosus (L. rhamnosus) original species word bank by 1:1.
5, use lactobacillus rhamnosus (L. rhamnosus) primordial seed to carry out amplification culture, set up lactobacillus rhamnosus (L. rhamnosus) work seed bank.
6, choose the source of lactobacillus rhamnosus (L. rhamnosus) work seed bank as strain, the step in the preparation of other step and Lactobacillus crispatus mycopowder is identical.The total viable count of lactobacillus rhamnosus (L. rhamnosus) mycopowder of preparation is 1 * 10
6To 1 * 10
12Between individual/g.
Four, a kind of capsular preparation of Lactobacillus that vaginitis is had treatment and preventive effect
Lactobacillus crispatus mycopowder and lactobacillus rhamnosus mycopowder being pressed the weight ratio of 1:1 mixes; Obtain lactobacillus mixing mycopowder; And then according to the part by weight of 1 g lactobacillus mixing mycopowder and 1 g microcrystalline Cellulose; Mix mycopowder and excipient, last filled capsules is promptly processed a kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect.Total viable count is 1 * 10 in prepared a kind of Lactobacillus capsule that vaginitis is had treatment and a preventive effect
6To 1 * 10
12Between individual/capsules.
Embodiment 2 ~ 6
One, the preparation of Lactobacillus crispatus mycopowder
Identical with the preparation process of embodiment 1, the total viable count of the Lactobacillus crispatus mycopowder of preparation is 1 * 10
6To 1 * 10
12Between individual/g.
Two, the preparation of lactobacillus rhamnosus mycopowder, bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder and bacillus bifidus mycopowder
Preparation lactobacillus rhamnosus seed bank similar methods among employing and the embodiment 1; Set up lactobacillus rhamnosus work seed bank, bacillus acidophilus work seed bank, Lactobacillus fermenti work seed bank and bacillus bifidus work seed bank respectively; Then with reference to the preparation process of the Lactobacillus crispatus mycopowder among the embodiment 1; Prepare lactobacillus rhamnosus mycopowder, bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder and bacillus bifidus mycopowder respectively, the total viable count of prepared lactobacillus rhamnosus mycopowder is 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of bacillus acidophilus's mycopowder is 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of Lactobacillus fermenti mycopowder is 1 * 10
6To 1 * 10
12Total viable count with the bacillus bifidus mycopowder between individual/g is 1 * 10
6To 1 * 10
12Between individual/g.
Three, a kind of capsular preparation of Lactobacillus that vaginitis is had treatment and preventive effect
Lactobacillus crispatus mycopowder and lactobacillus rhamnosus mycopowder, bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder and bacillus bifidus mycopowder are proportionally mixed; Obtain mixing mycopowder; To mix mycopowder then and excipient proportionally mixes, last filled capsules is promptly processed bent lactobacillus and bacillus acidophilus's bigeminy lactobacillus capsule.Concrete mycopowder and the ratio that adds seen table 1.
Embodiment 7 ~ 11
One, buys commercialization strain and set up seed bank
1, buys source clear and definite Lactobacillus crispatus strain, bacillus acidophilus (L. acidophilus) strain, Lactobacillus fermenti (L.fermentum) strain, lactobacillus rhamnosus (L. rhamnosus) strain and bacillus bifidus (Bifidobacterium) strain from the Chinese Academy of Sciences.
2, set up Lactobacillus crispatus, bacillus acidophilus (L. acidophilus) work seed bank, Lactobacillus fermenti (L.fermentum) work seed bank, lactobacillus rhamnosus (L. rhamnosus) work seed bank and bacillus bifidus (Bifidobacterium) seed bank of working after adopting method among the embodiment 1 to cultivate, identify.
Two,Adopt the method among the embodiment 1 to prepare Lactobacillus crispatus mycopowder, bacillus acidophilus (L. acidophilus) mycopowder, Lactobacillus fermenti (L.fermentum) mycopowder, lactobacillus rhamnosus (L. rhamnosus) mycopowder and bacillus bifidus (Bifidobacterium) mycopowder, the total viable count of the various lactobacillus mycopowder of preparation all is respectively 1 * 10
6To 1 * 10
12Between individual/g.
Three, a kind of capsular preparation of Lactobacillus that vaginitis is had treatment and preventive effect
Just Lactobacillus crispatus mycopowder and lactobacillus rhamnosus mycopowder, bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder and bacillus bifidus mycopowder proportionally mix; Obtain mixing mycopowder; To mix mycopowder then and excipient proportionally mixes, last filled capsules is promptly processed bent lactobacillus and bacillus acidophilus's bigeminy lactobacillus capsule.Concrete mycopowder and the ratio that adds seen table 2.
The subspecies character and the characteristic of lactic acid bacteria culturers are relatively stable; From different tissues or different brands yoghourt the functional characteristic of isolating lactobacillus lactis subsp similar; Basically can realize the object of the invention; So the needed lactobacillus inoculation of the embodiment of the invention be not limited to above in tissue or yoghourt isolating lactobacillus subspecies; All can be used as strain of the present invention for other patent document and the disclosed or commercial Lactobacillus crispatus of non-patent document, bacillus acidophilus, Lactobacillus fermenti, lactobacillus rhamnosus and bacillus bifidus, realize the object of the invention.
The capsular clinical research of Lactobacillus of the present invention
1, patient age is 62 years old, vaginitis medical history 12 years, the long-term abnormal flavour of vagina; Need through flushing with clean water commonly used, but flushing used the vagina lactobacillus capsule of certain brand to treat later less than a week then occurring abnormal flavour once more before 2 years; Continuous use recovery from illness in 30 days, but recurrence again after 4 months are before a year and a half; Voluntarily prepared a kind of of trial edition inventive embodiment 1 has the Lactobacillus capsule of treatment and preventive effect to vaginitis, uses oral and vagina while administration, continuous use drug withdrawal after 30 days; Observe continuously recurrence again after 12 months, during do not see any untoward reaction.The patient is for prevention of recurrence, and 2-3 month just oral one month Lactobacillus crispatus and lactobacillus rhamnosus bigeminy lactobacillus capsule recur so far as yet at interval.
2, patient age is 31 years old, and the scorching medical history of absence of vagina afterwards is in hospital 10 because of trauma infection contamination before; Diarrhoea and vaginal dryness appear after infect curing, pruritus is surplus January, the leucorrhea inspection shows that vagina cleanness degree is 4 degree, prepared a kind of of trial edition inventive embodiment 6 has vaginitis and treats and the Lactobacillus capsule of preventive effect voluntarily; Use oral and vagina administration simultaneously; 8 days symptom of diarrhea of continuous use are alleviated, and medication is vaginal dryness, pruritus transference cure after 14 days, and the leucorrhea inspection shows that vagina cleanness degree is 1 degree; Enteritis and vaginitis all are able to cure, during no any untoward reaction.
3, in certain hospital-based outpatient obstetrical clinic; Selected age that 38 examples come to go to a doctor and be 25 to 65 years old bacterial vaginitis patient; A kind of oral simultaneously and 20 days later check leucorrhea of external curing of Lactobacillus capsule that vaginitis had treatment and preventive effect of preparation among the use embodiment 7 after the patient agrees; Find that patient's vagina cleanness degree of about 76% (29/38) becomes more than 2 degree; The vaginitis symptom disappears, and vaginitis symptoms such as all the other patients' pruritus, abnormal flavour all have alleviation in various degree.Treat after 30 days 97% (37/38)) patient's vagina cleanness degree become more than 2 degree, the vaginitis symptom disappears, during any untoward reaction does not appear.
Above embodiment only is used to specify the present invention, rather than protection scope of the present invention is limited.Those skilled in the art can change and revise it after understand spirit of the present invention and principle and reach equivalent purpose, and these changes and modification all should be covered by among the present invention.
Claims (10)
1. one kind has the treatment and the Lactobacillus capsule of preventive effect to vaginitis; It is characterized in that: be enclosed with excipient and lactobacillus mixing mycopowder in the described capsule, described lactobacillus mixing mycopowder comprises Lactobacillus crispatus mycopowder and other lactobacillus subspecies mycopowder with the effect of adjustment intestinal microbial population.
2. a kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect according to claim 1; It is characterized in that: described Lactobacillus crispatus mycopowder is 1 with the weight ratio of other lactobacillus subspecies mycopowder with the effect of adjustment intestinal microbial population: (1 ~ 100), the weight ratio of described excipient and lactobacillus mixing mycopowder is (1 ~ 10): 1.
3. according to claim 1 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, and it is characterized in that: described Lactobacillus crispatus is the bacterial strain of separating in the healthy women vagina.
4. according to claim 1 and 2 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, it is characterized in that: described have other lactobacillus subspecies mycopowder of adjusting the intestinal microbial population effect and refer to one or more the mixture in bacillus acidophilus's mycopowder, Lactobacillus fermenti mycopowder, lactobacillus rhamnosus mycopowder and the bacillus bifidus mycopowder.
5. according to claim 1 and 2 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, it is characterized in that: described to have the lactobacillus subspecies mycopowder of adjusting the intestinal microbial population effect be the lactobacillus rhamnosus mycopowder.
6. according to claim 1 and 2 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, and it is characterized in that: described excipient is a microcrystalline Cellulose.
7. according to claim 4 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, it is characterized in that: the total viable count of described Lactobacillus crispatus mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of described bacillus acidophilus's mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of Lactobacillus fermenti mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of lactobacillus rhamnosus mycopowder be 1 * 10
6To 1 * 10
12Between individual/g, the total viable count of bacillus bifidus mycopowder be 1 * 10
6To 1 * 10
12Between individual/g.
8. according to claim 1 and 2 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, it is characterized in that: the total viable count of the lactobacillus mixing mycopowder that described capsule is interior be 1 * 10
6To 1 * 10
12Between individual/capsules.
9. a kind of Lactobacillus capsule that vaginitis is had treatment and preventive effect according to claim 1; It is characterized in that: be enclosed with excipient and lactobacillus mixing mycopowder in the described capsule; Described lactobacillus mixing mycopowder comprises Lactobacillus crispatus mycopowder and lactobacillus rhamnosus mycopowder; Said excipient is a microcrystalline Cellulose, wherein the Lactobacillus crispatus mycopowder: the lactobacillus rhamnosus mycopowder: the weight ratio of excipient is 1:1:1.
10. according to claim 1 a kind ofly have the treatment and the Lactobacillus capsule of preventive effect to vaginitis, it is characterized in that: described vaginitis is had treat and the capsular route of administration of Lactobacillus of preventive effect is oral and/or vaginal approach.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102539440A CN102727531A (en) | 2012-07-23 | 2012-07-23 | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102539440A CN102727531A (en) | 2012-07-23 | 2012-07-23 | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727531A true CN102727531A (en) | 2012-10-17 |
Family
ID=46984298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102539440A Pending CN102727531A (en) | 2012-07-23 | 2012-07-23 | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727531A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103911307A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and its uses |
| CN103911305A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and uses thereof |
| CN106852939A (en) * | 2016-11-08 | 2017-06-16 | 江西益盟科技有限公司 | Treat lactic bacteria composition of vaginitis and preparation method thereof |
| CN107596350A (en) * | 2017-11-01 | 2018-01-19 | 哈尔滨欧替药业有限公司 | A kind of recombinant human interferon alpha 2 ε vaginal expansion plugs and preparation method thereof |
| CN109674826A (en) * | 2019-01-31 | 2019-04-26 | 吉林省知遇科技有限公司 | A kind of probiotic composition for nursing female reproductive system |
| CN110201004A (en) * | 2019-06-27 | 2019-09-06 | 北京奥维森基因科技有限公司 | A kind of woman's probiotic composition, preparation method, its application and feminine care products |
| CN110960561A (en) * | 2019-12-31 | 2020-04-07 | 南昌诺汇医药科技有限公司 | Composite microbial inoculum for regulating balance of gynecological flora |
| CN111821321A (en) * | 2019-04-17 | 2020-10-27 | 吉林省知遇科技有限公司 | Probiotics composition for nursing female reproductive system |
| CN112501051A (en) * | 2020-11-05 | 2021-03-16 | 内蒙古普泽生物制品有限责任公司 | Probiotic compound preparation and application thereof in regulating vaginal flora and resisting HPV |
| CN113181345A (en) * | 2021-05-12 | 2021-07-30 | 济南万泉生物技术有限公司 | Probiotic gel for recovering and stabilizing vaginal microbial flora and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1556852A (en) * | 2001-09-20 | 2004-12-22 | �����ɷ� | Lactic acid producing bacteria for use as probiotic organisms in the human vagina |
-
2012
- 2012-07-23 CN CN2012102539440A patent/CN102727531A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1556852A (en) * | 2001-09-20 | 2004-12-22 | �����ɷ� | Lactic acid producing bacteria for use as probiotic organisms in the human vagina |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103911307A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and its uses |
| CN103911305A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and uses thereof |
| CN103911305B (en) * | 2013-01-05 | 2016-04-13 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus bacterial strain and uses thereof |
| CN103911307B (en) * | 2013-01-05 | 2016-04-13 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus bacterial strain and uses thereof |
| CN106852939A (en) * | 2016-11-08 | 2017-06-16 | 江西益盟科技有限公司 | Treat lactic bacteria composition of vaginitis and preparation method thereof |
| CN107596350B (en) * | 2017-11-01 | 2020-07-14 | 哈尔滨欧替药业有限公司 | Recombinant human interferon expandable vaginal suppository and preparation method thereof |
| CN107596350A (en) * | 2017-11-01 | 2018-01-19 | 哈尔滨欧替药业有限公司 | A kind of recombinant human interferon alpha 2 ε vaginal expansion plugs and preparation method thereof |
| CN109674826A (en) * | 2019-01-31 | 2019-04-26 | 吉林省知遇科技有限公司 | A kind of probiotic composition for nursing female reproductive system |
| CN111821321A (en) * | 2019-04-17 | 2020-10-27 | 吉林省知遇科技有限公司 | Probiotics composition for nursing female reproductive system |
| CN110201004A (en) * | 2019-06-27 | 2019-09-06 | 北京奥维森基因科技有限公司 | A kind of woman's probiotic composition, preparation method, its application and feminine care products |
| CN110960561A (en) * | 2019-12-31 | 2020-04-07 | 南昌诺汇医药科技有限公司 | Composite microbial inoculum for regulating balance of gynecological flora |
| CN110960561B (en) * | 2019-12-31 | 2020-10-16 | 江苏华庆农业发展有限公司 | Probiotic composition for regulating balance of gynecological flora |
| CN112501051A (en) * | 2020-11-05 | 2021-03-16 | 内蒙古普泽生物制品有限责任公司 | Probiotic compound preparation and application thereof in regulating vaginal flora and resisting HPV |
| CN112501051B (en) * | 2020-11-05 | 2023-01-10 | 内蒙古普泽生物制品有限责任公司 | Probiotic composite preparation and application thereof in vaginal flora regulation and HPV resistance |
| CN113181345A (en) * | 2021-05-12 | 2021-07-30 | 济南万泉生物技术有限公司 | Probiotic gel for recovering and stabilizing vaginal microbial flora and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727531A (en) | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis | |
| ES2670536T3 (en) | Lactobacillus crispatus and its application | |
| US20060127381A1 (en) | Live bacterial preparation of bacillus coagulans for the treatment of ulcerative colitis, method for producing the same and use thereof | |
| JP2009269922A (en) | Topical use of probiotic bacillus spore for preventing or controlling microbe infection | |
| CN104382685B (en) | A kind of preparation method of human vagina's probiotics-probio sheath | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN106860451A (en) | A kind of new opplication of rifamycin nitroimidazole coupling molecule | |
| CN108611295B (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN106957811B (en) | Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation | |
| CN108403725A (en) | Composition for treating digestive tract ulcer and its application | |
| CN113797158B (en) | Gynecological in-situ temperature-sensitive gel preparation containing active lactobacillus gasseri, and preparation and application thereof | |
| CN102512417B (en) | Compound rifaximin dry suspension for preventing and treating endometritis of livestock and preparation method for same | |
| CN1084612C (en) | Viracidal, bactericidal and spermicidal vaginal suppository | |
| CN101336938A (en) | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease | |
| CN116966206A (en) | Use of lactobacillus fermentum for the preparation of a product for the prevention and/or treatment of the colon of a laxative | |
| CN111471623A (en) | Composition of three lactobacilli and application thereof | |
| CN103156886A (en) | Application of bacteroides fragilis in preparation of composition for treating bacterial vaginitis | |
| CN107998154B (en) | Probiotics preparation for preventing and treating female diseases and preparation method and application thereof | |
| JPH02503800A (en) | Bacterial preparations for the prevention and treatment of inflammatory processes and allergic diseases | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN105534948B (en) | A kind of vagina active bacteria formulation and preparation method thereof being stored at room temperature | |
| US20210060091A1 (en) | Bacteroides ovatus for Relieving Endotoxin Infection and Application thereof | |
| CN107441121A (en) | A kind of fermentation crude extract of streptococcus salivarius and its preparation method and application | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121017 |